StageBio is delighted to announce that David Bruning is joining our team as our new CEO and President. Bringing over 25 years of leadership experience in a multitude of roles, including five years serving on the StageBio Board of Directors, Mr. Bruning's industry knowledge positions him to guide StageBio to a successful future.
Read the full press release here.
For additional questions, contact our team. StageBio is a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research.
513.204.4400
